Nolte, who is also a member of the Purdue University Center for Cancer Research, said that light scatter dynamics gives scientists and doctors detailed information about the likelihood that a chemotherapy drug will be effective for a patient. Nolte said they got results within 24 hours. This first study looked at biodynamic imaging in human ovarian cancer patients. “We’re looking for signs of apoptosis or what is known as the controlled death of cells,” said Nolte. “Apoptosis is the signal that indicates the effectiveness of chemotherapy on this patient’s tissues and tumors. For some cancers, so many treatment options are available that it is like a doctor trying to stick square pegs into circular holes until the desired result is found. We want to improve this process for patients. ”
Nolte has worked with several groups within the Purdue Entrepreneurship and Commercialization ecosystem, including the Purdue Foundry, developing business plans and finding management. AniDyn, a medical technology startup, was spun off from Purdue by Professors Nolte and John J. Turek. AniDyn focuses on developing and commercializing technologies for imaging living tissues. Nolte also works closely with the Purdue Research Foundation’s Office of Technology Commercialization to patent and license its technologies. (ANI)
Also read: OxyContin manufacturer Purdue pleads guilty to opioid practices and triggers spark opposition
These were the details of the news The study shows that about 60 percent of cancer patients do... for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at de24.news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.